## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.7% in upper entry zone (4.0-10.0%), top 5% cross-sectional ranking. Caution: MRS_5 (-0.1%) diverging from MRS_20, watch for reversal. Outperforming sector by 14.2%. Caution: declining volume (59% of avg), momentum weakening (-9.0% MRS), overbought RSI (89).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($97.23)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-28 | Stifel | $105 | $80 | +31% |
| 2025-11-25 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-24 | Benchmark | $0 | $0 | 0% |
| 2025-11-24 | Jefferies | $105 | $90 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-28 | Stifel | down | Hold |
| 2025-11-25 | Canaccord Genui | down | Hold |
| 2025-11-24 | Benchmark | down | Hold |
| 2025-11-24 | Jefferies | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-9.0% 5d) with bearish MACD, trend may be turning.
2. Overbought RSI (89) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +24%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 90.6x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Analyst sentiment positive (6 raises, avg +24%). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 1.42 |
| 52W Range | $38.81 - $101.87 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 90.6 |
| Current P/E | 299.4 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 18.7% to 9.7% (-9.0% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 94th percentile. MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 12.0% shows strong absolute momentum above own 20MA. Outperforming sector by 14.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 89, risk of mean reversion. Volume at 59% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.65% (CS: 95) | Strong |
| RSI_14 | 89.4 | Overbought |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 1.120x | Above |
| vs SMA50 | 1.379x | Above |
| vs SMA200 | 1.822x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $101.25
- **Stop Loss:** $97.23 (4.0% risk)
- **Target:** $107.28 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $7,492.50
- **Portfolio %:** 7.49%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*